Fingolimod (FTY720): First approved oral therapy for multiple sclerosis.
作者信息
Sharma Sushil, Mathur A G, Pradhan Sapna, Singh D B, Gupta Sparsh
机构信息
Department of Pharmacology, Army College of Medical Sciences, Delhi Cantt, New Delhi, India.
出版信息
J Pharmacol Pharmacother. 2011 Jan;2(1):49-51. doi: 10.4103/0976-500X.77118.
Abstract
摘要
相似文献
1
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis.芬戈莫德（FTY720）：首个获批用于治疗多发性硬化症的口服药物。
J Pharmacol Pharmacother. 2011 Jan;2(1):49-51. doi: 10.4103/0976-500X.77118.
2
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.芬戈莫德（FTY720）：一种治疗多发性硬化症的口服药物的发现和开发。
Nat Rev Drug Discov. 2010 Nov;9(11):883-97. doi: 10.1038/nrd3248. Epub 2010 Oct 29.
3
Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.芬戈莫德（FTY720）在多发性硬化症中的潜在再生作用：髓鞘再生过程综述
J Neurosci Res. 2020 Mar;98(3):524-536. doi: 10.1002/jnr.24509. Epub 2019 Aug 5.
4
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.基于证据评估芬戈莫德在复发型多发性硬化症治疗中的潜在用途。
Core Evid. 2011;6:13-21. doi: 10.2147/CE.S10101. Epub 2011 Jan 6.
5
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.FTY720（芬戈莫德）在多发性硬化症动物模型中的疗效需要星形胶质细胞鞘氨醇 1-磷酸受体 1（S1P1）的调节。
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.
6
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.口服芬戈莫德治疗复发缓解型多发性硬化症 评价：Kappos L、Radue E-M、O'Connor P 等人。口服芬戈莫德治疗复发型多发性硬化症的安慰剂对照试验。《新英格兰医学杂志》2010；362：387-401；以及 Cohen JA、Barkhof F、Comi G 等人。口服芬戈莫德或肌肉内干扰素治疗复发型多发性硬化症。《新英格兰医学杂志》2010；362：402-15。
Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671.
7
Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis.一名正在服用芬戈莫德（FTY720）治疗多发性硬化症的患者发生急性前葡萄膜炎。
Case Rep Ophthalmol. 2016 Dec 8;7(3):284-288. doi: 10.1159/000453392. eCollection 2016 Sep-Dec.
8
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].[FTY720（芬戈莫德）作为多发性硬化症的一种新治疗选择]
Nervenarzt. 2007 Oct;78(10):1200-8. doi: 10.1007/s00115-007-2298-9.
9
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.多发性硬化症药物芬戈莫德（FTY720）可刺激神经元基因表达、轴突生长和再生。
Exp Neurol. 2016 May;279:243-260. doi: 10.1016/j.expneurol.2016.03.012. Epub 2016 Mar 12.
10
The emerging role of FTY720 (Fingolimod) in cancer treatment.FTY720（芬戈莫德）在癌症治疗中的新作用。
Oncotarget. 2016 Apr 26;7(17):23106-27. doi: 10.18632/oncotarget.7145.
引用本文的文献
1
A Review Discussing Synthesis and Translational Studies of Medicinal Agents Targeting Sphingolipid Pathways.一篇关于靶向鞘脂途径的药物合成与转化研究的综述
Biomolecules. 2025 Jul 16;15(7):1022. doi: 10.3390/biom15071022.
2
Oligodendroglia vulnerability in the human dorsal striatum in Parkinson's disease.帕金森病患者人类背侧纹状体中少突胶质细胞的易损性
Acta Neuropathol. 2025 May 5;149(1):46. doi: 10.1007/s00401-025-02884-5.
3
Potential of Liposomal FTY720 for Bone Regeneration: Proliferative, Osteoinductive, Chemoattractive, and Angiogenic Properties Compared to Free Bioactive Lipid.脂质体FTY720促进骨再生的潜力：与游离生物活性脂质相比，其增殖、骨诱导、趋化和血管生成特性
Int J Nanomedicine. 2025 Jan 7;20:239-265. doi: 10.2147/IJN.S494512. eCollection 2025.
4
Multiple sphingolipid-metabolizing enzymes modulate influenza virus replication.多种鞘脂代谢酶调节流感病毒复制。
Virology. 2025 Feb;603:110367. doi: 10.1016/j.virol.2024.110367. Epub 2024 Dec 22.
5
Accelerating Oral Wound Healing Using Bilayer Biomaterial Delivery of FTY720 Immunotherapy.使用FTY720免疫疗法的双层生物材料递送促进口腔伤口愈合。
Adv Healthc Mater. 2024 Dec;13(30):e2401480. doi: 10.1002/adhm.202401480. Epub 2024 Oct 10.
6
The functional antagonist of sphingosine-1-phosphate, FTY720, impairs gut barrier function.鞘氨醇-1-磷酸的功能性拮抗剂FTY720会损害肠道屏障功能。
Front Pharmacol. 2024 Aug 19;15:1407228. doi: 10.3389/fphar.2024.1407228. eCollection 2024.
7
FTY720 Reduces the Biomass of Biofilms in in a Dose-Dependent Manner.FTY720以剂量依赖的方式减少生物膜的生物量。
Antibiotics (Basel). 2024 Jul 4;13(7):621. doi: 10.3390/antibiotics13070621.
8
Platelet Membrane Nanocarriers Cascade Targeting Delivery System to Improve Myocardial Remodeling Post Myocardial Ischemia-Reperfusion Injury.血小板膜纳米载体级联靶向递送系统改善心肌缺血再灌注损伤后的心肌重塑
Adv Sci (Weinh). 2024 Apr;11(16):e2308727. doi: 10.1002/advs.202308727. Epub 2024 Feb 12.
9
Pleiotropic effect of intramucosal injection of FTY720 on angiogenesis and tissue healing after free gingival graft surgery: a comparative experimental study in rabbits.FTY720 黏膜内注射对游离龈移植术后血管生成和组织愈合的多效作用：兔的对比性实验研究。
Clin Oral Investig. 2023 Dec 28;28(1):47. doi: 10.1007/s00784-023-05450-z.
10
Drivers of Chronic Pathology Following Ischemic Stroke: A Descriptive Review.缺血性脑卒中后慢性病理的驱动因素：描述性综述。
Cell Mol Neurobiol. 2023 Dec 19;44(1):7. doi: 10.1007/s10571-023-01437-2.
本文引用的文献
1
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.口服芬戈莫德治疗复发缓解型多发性硬化症。
Drugs Today (Barc). 2010 May;46(5):315-25. doi: 10.1358/dot.2010.46.5.1497556.
2
Oral therapy for multiple sclerosis--sea change or incremental step?多发性硬化症的口服疗法——是重大变革还是渐进式进展？
N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.
3
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
4
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
5
Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.酮康唑通过抑制CYP4F2在药物相互作用中提高芬戈莫德的血药浓度。
J Clin Pharmacol. 2009 Feb;49(2):212-8. doi: 10.1177/0091270008329553. Epub 2008 Dec 31.
6
FTY720 modulates human oligodendrocyte progenitor process extension and survival.FTY720调节人少突胶质前体细胞的突起延伸和存活。
Ann Neurol. 2008 Jan;63(1):61-71. doi: 10.1002/ana.21227.
7
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors.免疫调节剂FTY720对少突胶质前体细胞具有直接的细胞保护作用。
J Pharmacol Exp Ther. 2007 Nov;323(2):626-35. doi: 10.1124/jpet.107.123927. Epub 2007 Aug 28.
8
Oral fingolimod (FTY720) for relapsing multiple sclerosis.口服芬戈莫德（FTY720）用于复发型多发性硬化症。
N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643.
9
Immunology of multiple sclerosis.多发性硬化症的免疫学
Annu Rev Immunol. 2005;23:683-747. doi: 10.1146/annurev.immunol.23.021704.115707.
10
Overview of FTY720 clinical pharmacokinetics and pharmacology.FTY720临床药代动力学与药理学概述。
Ther Drug Monit. 2004 Dec;26(6):585-7. doi: 10.1097/00007691-200412000-00001.
Zotero 插件